Replicor宣布在EASL上展示实验终点数据

StephenW

Replicor announces presentation of experimental endpoint data at EASL

MONTREAL, September 10th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the late breaking presentation of experimental endpoint data from its most recent REP 301/301-LTF and REP 401 studies at the Digital ILC 2020.

Conducted in collaboration with Abbott Diagnostics, a variety of experimental virologic markers were analyzed during therapy and follow-up after treatment with NAP-based combination therapy in HBeAg HBV / HDV co-infection (REP 301/301-LTF) and HBeAg negative HBV infection (REP 401).  These included ultralow HBsAg (<0.005 IU/mL), HBV pgRNA, HBcrAg and HBsAg immune complexes.

During NAP-based therapy, HBsAg clearance was shown to extend to < 0.005 IU/mL with clearance of both HBV RNA and HBcrAg.  All of these experimental milestones were maintained in patients with functional cure of HBV.  HBsAg immune complexes declined early in therapy and this decline generally continued throughout therapy and universally during follow-up in participants with functional cure.

Replicor’s CSO, Dr. Andrew Vaillant commented, “These experimental endpoint data demonstrate not only the very effective nature of HBsAg clearance with NAP-based therapy, but also the effective silencing and or erosion of cccDNA.  They also demonstrate the profound control of infection in patients that achieve functional cure with NAPs.   We are also very encouraged by the absence of HBsAg immune complexes in participants with functional cure, which strongly suggests the efficient removal of integrated HBV DNA from the liver.”

Replicor’s presentation is available on the company’s website at www.replicor.com/science/conference-presentations.  For further information about the Digital ILC 2020: https://ilc-congress.eu/

StephenW

Replicor宣布在EASL上展示实验终点数据

蒙特利尔，2020年9月10日–一家私有生物制药公司Replicor Inc.，其针对慢性乙型和丁型肝炎感染患者的功能性治疗，宣布了最新的REP 301 / 301-LTF和REP实验终点数据的最新发布2020年ILC上的401项研究。

在与Abbott Diagnostics合作进行的治疗过程中以及在基于NAP的联合治疗HBeAg HBV / HDV合并感染（REP 301 / 301-LTF）和HBeAg阴性HBV感染的治疗过程中和随访后分析了多种实验病毒学标志物（REP 401）。这些包括超低HBsAg（<0.005 IU / mL），HBV pgRNA，HBcrAg和HBsAg免疫复合物。

在基于NAP的治疗过程中，随着HBV RNA和HBcrAg的清除，HBsAg清除率可扩展至<0.005 IU / mL。 HBV功能治愈的患者均保持了所有这些实验性里程碑。 HBsAg免疫复合物在治疗早期下降，并且这种下降通常在整个治疗过程中以及在具有功能性治愈的参与者的随访期间普遍持续。

复制者的CSO，Andrew Vaillant博士评论说：“这些实验终点数据不仅显示了基于NAP的疗法清除HBsAg的非常有效的性质，而且还证明了cccDNA的有效沉默和/或侵蚀。他们还证明了可以通过NAP实现功能治愈的患者对感染的深刻控制。功能治愈的参与者中不存在HBsAg免疫复合物，这也使我们感到鼓舞，这强烈表明从肝脏中有效去除了整合的HBV DNA。”

Replicor的演示文稿可以在公司的网站上找到，网址为www.replicor.com/science/conference-presentations。有关Digital ILC 2020的更多信息，请访问：https：//ilc-congress.eu/

齐欢畅

平凡之路123

接下来，该公司会继续随访十年，请大家关注。

乙肝人1949

不过有进步，发布的数据报告，基夲告别鸭子，老鼠一类，从动物世界走向人类世界